Inclusion Criteria:  Patients who have a clinical suspicion of prostate cancer defined by PI-RADS 3, 4 or 5 lesions detected on MRI as well as patients with negative prostate MRI or those with PI-RADS 1 or 2 lesions if they have continued suspicion for prostate cancer. Patients who cannot undergo MRI imaging but have a clinical suspicion for prostate cancer based on serum PSA level, family history or clinical examination (positive digital rectal examination) can also be included. Able to tolerate PET/CT scans Informed consent must be given and signed  Exclusion Criteria:  Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks Known allergy against Ga-68 PSMA Prior prostate biopsy within the last 2 weeks